Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type

被引:1
|
作者
Hayes, Corey J. [1 ,2 ,3 ]
Raciborski, Rebecca A. [3 ,4 ,5 ]
Nowak, Matthew [6 ]
Acharya, Mahip [2 ,7 ]
Nunes Jr, Edward V. [8 ]
Winhusen, T. John [9 ,10 ]
机构
[1] Univ Arkansas Med Sci, Coll Med, Dept Biomed Informat, Little Rock, AR USA
[2] Univ Arkansas Med Sci, Inst Digital Hlth & Innovat, Coll Med, Little Rock, AR USA
[3] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, 4301 W Markham St,Slot 782, North Little Rock, AR 72205 USA
[4] Cent Arkansas Vet Healthcare Syst, Behav Hlth Qual Enhancement Res Initiat, North Little Rock, AR USA
[5] Cent Arkansas Vet Healthcare Syst, Evidence Policy & Implementat Ctr, North Little Rock, AR USA
[6] Univ Arkansas Med Sci, Coll Med, Little Rock, AR USA
[7] Univ Arkansas Med Sci, Coll Med, Dept Obstet & Gynecol, Little Rock, AR USA
[8] Columbia Univ, Irving Med Ctr, Dept Psychiat, Div Subst Use Disorders, New York, NY USA
[9] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA
[10] Univ Cincinnati, Coll Med, Ctr Addict Res, Cincinnati, OH USA
基金
美国国家卫生研究院;
关键词
Geographic disparities; medication treatment for opioid use disorder; opioid use disorder; overdose; racial disparities; veterans; EXTENDED-RELEASE NALTREXONE; BUPRENORPHINE TREATMENT; DEPENDENCE; RETENTION; METHADONE; CARE; MAINTENANCE; THERAPY; RELAPSE; ACCESS;
D O I
10.1111/add.16659
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
AimThis study: (1) estimated the effect of early discontinuation of medication for opioid use disorder (MOUD) on overdose probability and (2) measured the relationship between patient characteristics and early discontinuation probability for each MOUD type.Design, setting and participantsThis was a retrospective cohort using electronic health record data from the US Veterans Healthcare Administration. Participants were veterans initiating MOUD with buprenorphine (BUP), methadone (MET) or extended-release naltrexone (XR-NTX) from fiscal years 2012-19. A total of 39 284 veterans met eligibility with 22 721 (57.8%) initiating BUP, 12 652 (32.2%) initiating MET and 3911 (10.0%) initiating XR-NTX.MeasurementsMeasurements (1) determined whether the veteran experienced an overdose in the 365 days after MOUD initiation (primary) and (2) early discontinuation of MOUD, defined as discontinuation before 180 days (secondary). We assumed that unobserved patient characteristics would jointly influence the probability of discontinuation and overdose. and estimated the joint distribution with a bivariate probit model.FindingsWe found that 9.0% of BUP initiators who experienced an overdose above the predicted 3.9% had no veteran-discontinued BUP early; findings for XR-NTX were similar, with 12.2% of initiators overdosing above the predicted 4.5%, but this was statistically inconclusive. We found no relationship between early discontinuation and overdose for MET initiators, probably due to the high risk of both events. The patient characteristics included in our post-estimation exploratory analysis of early discontinuation varied by MOUD type, with between 14 (XR-NTX) and 25 (BUP) tested. The only characteristics with at least one level showing a statistically significant change in probability of early discontinuation for all three MOUD types were geography and prior-year exposure to psychotherapy, although direction and magnitude varied.ConclusionEarly discontinuation of buprenorphine, and probably extended-release naltrexone, appears to be associated with a greater probability of experiencing a fatal or non-fatal overdose among US veterans receiving medication for opioid use disorder (MOUD); methadone does not show the same association. There is no consistent set of characteristics among early discontinuers by MOUD type.
引用
收藏
页码:138 / 151
页数:14
相关论文
共 25 条
  • [21] Co-occurring alcohol use disorder and obesity in US military veterans: Prevalence, risk factors, and clinical features
    Carr, Meagan M.
    Serowik, Kristin L.
    Na, Peter J.
    Potenza, Marc N.
    Martino, Steve
    Masheb, Robin M.
    Pietrzak, Robert H.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 150 : 64 - 70
  • [22] Prevalence, risk and protective factors of alcohol use disorder during the COVID-19 pandemic in US military veterans
    Na, Peter J.
    Norman, Sonya B.
    Nichter, Brandon
    Hill, Melanie L.
    Rosen, Marc I.
    Petrakis, Ismene L.
    Pietrzak, Robert H.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 225
  • [23] Early COVID-Related pandemic impacts and subsequent opioid outcomes among persons receiving medication for opioid use disorder: a secondary data analysis of a Type-3 hybrid trial
    Tim Janssen
    Bryan R. Garner
    Julia Yermash
    Kimberly R. Yap
    Sara J. Becker
    Addiction Science & Clinical Practice, 18
  • [24] Early COVID-Related pandemic impacts and subsequent opioid outcomes among persons receiving medication for opioid use disorder: a secondary data analysis of a Type-3 hybrid trial
    Janssen, Tim
    Garner, Bryan R.
    Yermash, Julia
    Yap, Kimberly R.
    Becker, Sara J.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2023, 18 (01)
  • [25] Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial
    Socias, M. Eugenia
    Cui, Zishan
    Le Foll, Bernard
    Lei, Jingxin
    Stewart, Sherry
    Anand, Rohan
    Jutras-Aswad, Didier
    HIV MEDICINE, 2024, 25 (07) : 817 - 825